Marco Cola

Dr. Marco Cola

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Mayo Clinic Proceedings: Innovations, Quality & Outcomes
Verified
Journal Article
Open access
LSLuca Spiezia
Luca Spiezia
ECElena Campello
Elena Campello
MCMarco Cola
Marco Cola
FPFrancesco Poletto
Francesco Poletto
LCLorenzo Cerruti
Lorenzo Cerruti
PSPaolo Simioni
Paolo Simioni
To conduct a comprehensive evaluation of coagulation profiles—via traditional and whole blood thromboelastometry tests—in coronavirus disease 2019 (COVID-19)–positive vs COVID-19–negative patients admitted to medical wards for acute pneumonia. We enrolled all consecutive patients admitted to internal medicine wards of Padova University Hospital between 7 March and 30 April, 2020, for COVID-19–related pneumonia (cases) vs non–COVID-19 pneumonia (controls). A group of healthy individuals acted as baseline for thromboelastometry parameters. Fifty-six cases (mean age, 64±15 years; male/female, 37/19) and 56 controls (mean age, 76±11 years; male/female, 35/21) were enrolled. Cases and controls exhibited markedly hypercoagulable thromboelastometry profiles vs healthy individuals, mainly characterized by a significantly shorter propagation phase of coagulation (clot formation time) and significantly increased maximum clot firmness (P<.001 for all comparisons). Patients with COVID-19 pneumonia had significantly shorter clot formation time and higher maximum clot firmness (P<.01 and P<.05, respectively, for all comparisons) than did controls. Patients admitted to internal medicine wards for COVID-19 pneumonia presented a markedly prothrombotic state, which seems peculiar to COVID-19 rather than pneumonia itself.

13 March 2024 in Viruses
Verified
Journal Article
Open access
PDF file
LMLaura Manuto
Laura Manuto
MBMartina Bado
Martina Bado
MCMarco Cola
Marco Cola
EVElena Vanzo
Elena Vanzo
MAMaria Antonello
Maria Antonello
Enrico LavezzoEnrico Lavezzo
Enrico Lavezzo
During the COVID-19 pandemic, immunosuppressed patients showed prolonged SARS-CoV-2 infections, with several studies reporting the accumulation of mutations in the viral genome. The weakened immune system present in these individuals, along with the effect of antiviral therapies, are thought to create a favourable environment for intra-host viral evolution and have been linked to the emergence of new viral variants which strongly challenged containment measures and some therapeutic treatments. To assess whether impaired immunity could lead to the increased instability of viral genomes, longitudinal nasopharyngeal swabs were collected from eight immunocompromised patients and fourteen non-immunocompromised subjects, all undergoing SARS-CoV-2 infection. Intra-host viral evolution was compared between the two groups through deep sequencing, exploiting a probe-based enrichment method to minimise the possibility of artefactual mutations commonly generated in amplicon-based methods, which heavily rely on PCR amplification. Although, as expected, immunocompromised patients experienced significantly longer infections, the acquisition of novel intra-host viral mutations was similar between the two groups. Moreover, a thorough analysis of viral quasispecies showed that the variability of viral populations in the two groups is comparable not only at the consensus level, but also when considering low-frequency mutations. This study suggests that a compromised immune system alone does not affect SARS-CoV-2 within-host genomic variability.

11 September 2024 in Rheumatology
Verified
Journal Article
Closed access
PDF file
MSMariangela Salvato
Mariangela Salvato
FFFrancesca Frizzera
Francesca Frizzera
KKKiren Khalid
Kiren Khalid
SBSara Bindoli
Sara Bindoli
MCMarco Cola
Marco Cola
AGAlessandro Giollo
Alessandro Giollo
Mariangela Salvato, Francesca Frizzera, Kiren Khalid, Sara Bindoli, Marco Cola, Marco Trevenzoli, Marny Fedrigo, Annalisa Angelini, Andrea Doria, Alessandr

21 March 2022 in Digestive and Liver Disease
Verified
Journal Article
Closed access
MTMichele Tonon
Michele Tonon
SIS. Incicco
S. Incicco
VCV. Calvino
V. Calvino
ABAlessandra Brocca
Alessandra Brocca
AAA. Accetta
A. Accetta
PAP. Angeli
P. Angeli

4 December 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
LMLaura Manuto
Laura Manuto
MBMartina Bado
Martina Bado
MCMarco Cola
Marco Cola
EVElena Vanzo
Elena Vanzo
MAMaria Antonello
Maria Antonello
Enrico LavezzoEnrico Lavezzo
Enrico Lavezzo
During the COVID-19 pandemic, immunosuppressed patients showed prolonged SARS-CoV-2 infections, with several studies reporting the accumulation of mutations in the viral genome. The weakened immune system present in these individuals, along with the effect of antiviral thera-pies, are thought to create a favourable environment for intra-host viral evolution and have been linked to the emergence of new viral variants, which strongly challenged the containment measures and some therapeutic treatments. To assess whether an impaired immunity could lead to an increased instability of viral genomes, longitudinal nasopharyngeal swabs were collected from eight immunocompromised patients and fourteen non-immunocompromised subjects, all undergoing SARS-CoV-2 infection. Intra-host viral evolution was compared between the two groups through deep sequencing, exploiting a probe-based enrichment method to minimize the possibility of artefactual mutations commonly generated in amplicon-based methods, which heavily rely on PCR amplification. Although, as expected, immunocompromised patients expe-rienced significantly longer infections, the acquisition of novel intra-host viral mutations was similar between the two groups. Moreover, a thorough analysis of viral quasispecies showed that the variability of viral populations in the two groups is comparable not only at the consensus level, but also when considering low frequency mutations. This study suggests that a compro-mised immune system alone does not affect SARS-CoV-2 within-host genomic variability.

8 July 2025 in Rheumatology
Verified
Journal Article
Closed access
MSMariangela Salvato
Mariangela Salvato
MCMarco Cola
Marco Cola
ACAnnamaria Cattelan
Annamaria Cattelan
ADAndrea Doria
Andrea Doria
AGAlessandro Giollo
Alessandro Giollo